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eTable 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
Section/item Item 
No 
Description Addressed on 
page number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym 1 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry 3 
2b All items from the World Health Organization Trial Registration Data Set 3 
(ISRCTN1694254) 
Protocol version 3 Date and version identifier - 
Funding 4 Sources and types of financial, material, and other support 23 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors 1, 23 
5b Name and contact information for the trial sponsor 23 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
24 
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 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
 
 
 
21 
Introduction 
   
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
5-8 
 6b Explanation for choice of comparators 7-8 
Objectives 7 Specific objectives or hypotheses 9-10 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 
 
10 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
16 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists) 
13, Fig. 2 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered 
15-16 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease) 
18, 20 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests) 
- 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial - 
 3 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
 
7-8, 16, Table 1 
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figure) 
Fig. 2, 15-16 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
14 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size 15 
Methods: Assignment of interventions (for controlled trials) 
 
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 
or assign interventions 
14 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned 
14 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions 
14 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
14 
 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
20 
Methods: Data collection, management, and analysis 
 
 4 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
16, Table 1 
 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
- 
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
21-22 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
14 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) 14 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation) 
- 
 
Methods: Monitoring 
 
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
21 
 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
N/A 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
20 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
- 
Ethics and dissemination  
 5 
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 20 
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
- 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
21 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
21 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
in order to protect confidentiality before, during, and after the trial 
21-22 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site 24 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators 
- 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial 
participation 
- 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
22 
 31b Authorship eligibility guidelines and any intended use of professional writers - 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code - 
Appendices 
   
Informed consent 
materials 
32 Model consent form and other related documentation given to participants and authorised surrogates Appendix 1 
 6 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
- 
*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. 
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
 
